Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-023569
Filing Date
2025-08-13
Accepted
2025-08-13 17:01:23
Documents
81
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1339987
2 EX-10.2 ex10-2.htm EX-10.2 71314
3 EX-10.3 ex10-3.htm EX-10.3 49922
4 EX-10.4 ex10-4.htm EX-10.4 22335
5 EX-31.1 ex31-1.htm EX-31.1 18606
6 EX-31.2 ex31-2.htm EX-31.2 18506
7 EX-32.1 ex32-1.htm EX-32.1 8186
8 EX-32.2 ex32-2.htm EX-32.2 8103
  Complete submission text file 0001641172-25-023569.txt   7578844

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE aktx-20250630.xsd EX-101.SCH 62745
10 XBRL CALCULATION FILE aktx-20250630_cal.xml EX-101.CAL 62384
11 XBRL DEFINITION FILE aktx-20250630_def.xml EX-101.DEF 308268
12 XBRL LABEL FILE aktx-20250630_lab.xml EX-101.LAB 528108
13 XBRL PRESENTATION FILE aktx-20250630_pre.xml EX-101.PRE 419479
83 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1177068
Mailing Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210
Business Address 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 (646) 350-0702
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-36288 | Film No.: 251212668
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)